LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

Search

Becton Dickinson and Co

Suletud

Sektor Tervishoid

229.06 1.88

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

228.47

Max

229.45

Põhinäitajad

By Trading Economics

Sissetulek

255M

537M

Müük

344M

5.1B

P/E

Sektori keskmine

47.614

23.904

Aktsiakasum

3.17

Kasumimarginaal

10.634

Töötajad

73,000

EBITDA

215M

1.3B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+22.21 upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. aug 2024

Järgmine dividendimakse kuupäev

27. sept 2024

Järgmine aktsia dividendi kuupäev (ex-date)

5. sept 2024

Turustatistika

By TradingEconomics

Turukapital

-1.7B

66B

Eelmine avamishind

227.18

Eelmine sulgemishind

229.06

Uudiste sentiment

By Acuity

12%

88%

6 / 369 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Becton Dickinson and Co Graafik

Seotud uudised

3. juuni 2024, 11:18 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

2. mai 2024, 11:07 UTC

Tulu

Becton Dickinson Shakes Up 2024 Outlook After Growing 2Q Sales, Earnings

1. veebr 2024, 12:04 UTC

Tulu

Becton Dickinson Lifts 2024 Outlook After Sales Rise in 1Q

4. juuni 2024, 17:26 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3. juuni 2024, 15:30 UTC

Kuumad aktsiad

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3. juuni 2024, 13:26 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3. juuni 2024, 12:25 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

3. juuni 2024, 11:03 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2B in Cash

3. juuni 2024, 10:40 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences To Sell Its Critical Care Product Group For $4.2 Billion To Becton Dickinson -- MarketWatch

3. juuni 2024, 10:32 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson: Acquired Business Has About 4,500 Employees >BDX EW

3. juuni 2024, 10:31 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson: Acquired Business Generated More Than $900 Million Revenue in 2023 >BDX

3. juuni 2024, 10:31 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson: Deal Expands Portfolio of Smart Connected Care Solutions >BDX EW

3. juuni 2024, 10:30 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson to Buy Edwards Lifesciences Critical Care Product Group for $4.2 Billion >BDX EW

3. juuni 2024, 10:30 UTC

Omandamised, ülevõtmised, äriostud

BD To Acquire Edwards Lifesciences' Critical Care Product Group For $4.2 Billion To Expand Smart Connected Care Solutions And Become An Advanced Monitoring Technology Leader >BDX EW

2. mai 2024, 10:35 UTC

Tulu

Becton Dickinson Had Seen FY24 Adjusted EPS $12.82-$13.06 >BDX

2. mai 2024, 10:34 UTC

Tulu

Becton Dickinson Raises FY24 View To Adj EPS $12.95-Adj EPS $13.15 >BDX

2. mai 2024, 10:34 UTC

Tulu

Becton Dickinson Still Sees FY24 Organic Revenue Growth of 5.5%-6.25% >BDX

2. mai 2024, 10:33 UTC

Tulu

Becton Dickinson Had Seen FY24 Revenue $20.2B-$20.4B >BDX

2. mai 2024, 10:33 UTC

Tulu

Becton Dickinson Cuts FY24 View To Rev $20.1B-$20.3B >BDX

2. mai 2024, 10:30 UTC

Tulu

Becton Dickinson 2Q Net $537M >BDX

2. mai 2024, 10:30 UTC

Tulu

Becton Dickinson 2Q Adj EPS $3.17 >BDX

2. mai 2024, 10:30 UTC

Tulu

Becton Dickinson 2Q EPS $1.85 >BDX

2. mai 2024, 10:30 UTC

Tulu

Becton Dickinson 2Q Rev $5B >BDX

27. märts 2024, 21:59 UTC

Omandamised, ülevõtmised, äriostud

3M's Healthcare Spinoff Stock Fell. This Is What It's Worth. -- Barrons.com

27. märts 2024, 09:15 UTC

Omandamised, ülevõtmised, äriostud

3M's Healthcare Spinoff Stock Is Trading. This Is What It's Worth. -- Barrons.com

1. veebr 2024, 11:34 UTC

Tulu

Becton Dickinson Sees FY24 Currency-Neutral Rev Growth 4.75%-5.5% >BDX

1. veebr 2024, 11:33 UTC

Tulu

Becton Dickinson Sees FY24 Organic Rev Growth 5.5%-6.25% >BDX

1. veebr 2024, 11:30 UTC

Tulu

Becton Dickinson 1Q Net $281M >BDX

1. veebr 2024, 11:30 UTC

Tulu

Becton Dickinson Sees FY Adj EPS $12.82-Adj EPS $13.06 >BDX

1. veebr 2024, 11:30 UTC

Tulu

Becton Dickinson 1Q EPS 96c >BDX

Võrdlus sarnastega

Hinnamuutus

Becton Dickinson and Co Prognoos

Hinnasiht

By TipRanks

22.21% tõus

12 kuu keskmine prognoos

Keskmine 280 USD  22.21%

Kõrge 312 USD

Madal 255 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Becton Dickinson and Co 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

8

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

227.69 / 229.12Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

6 / 369 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Becton Dickinson and Co

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through segments such as BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.